Insider Transaction Report for Arcellx, Inc.

Kristin Myers, a director at Arcellx, Inc., reported a disposition of stock options on April 28, 2026. These options, which were for Arcellx Common Stock, were canceled and converted into the right to receive a cash payment and a contractual contingent value right, as per the Agreement and Plan of Merger with Gilead Sciences, Inc. The disposed options included 16,829 shares with an exercise price of $69.87 and 1,784 shares with an exercise price of $63.68. All reported options were held indirectly and had a post-transaction share count of zero. This transaction is part of the merger process where Arcellx, Inc. became a wholly owned subsidiary of Gilead Sciences, Inc. through a subsidiary merger.